News | Mammography | May 01, 2017

New JACR study finds less frequent or delayed screening does not impact breast cancer overdiagnosis frequency

Breast Cancers Found by Mammography Do Not Regress If Left Untreated

May 1, 2017 — Breast cancers detected by mammography screening do not spontaneously disappear or regress if left untreated, according to a new study published in the Journal of the American College of Radiology (JACR). The scientific findings contradict claims that many cancers found via mammography may simply “go away” if left undiscovered or untreated.

Among all practices involved in the study, 25,281 screen-detected invasive breast cancers and 9,360 cases of screen-detected ductal carcinoma in situ were reported over the 10-year study period. Among these cancers, there were 240 cases of untreated invasive breast cancer and 239 cases of untreated ductal carcinoma in situ. None were reported to have spontaneously disappeared or regressed at next mammography.

An unknown percentage of these 479 cases represent overdiagnosis, but because all untreated screen-detected cancers were visible and suspicious for malignancy at next mammographic examination, delaying the onset of screening (from age 40 to ages 45 or 50) or increasing the interval between screenings (biennial vs annual) should not reduce the frequency of overdiagnosis. 

Medical science cannot yet determine which cancers will or will not advance to kill the person afflicted.

For more information: www.jacr.org


Related Content

News | FDA

Feb. 2, 2026 — Imagion Biosystems, Ltd. has submitted an Investigational New Drug (IND) application with the U.S. Food ...

Time February 02, 2026
arrow
News | Breast Imaging | Washington University

Jan. 22, 2026 — In breast cancer, a biopsy is the only diagnostic procedure that can determine if a suspicious lump or ...

Time January 29, 2026
arrow
News | Radiation Oncology

Jan. 27, 2026 — Researchers at the Icahn School of Medicine at Mount Sinai, in collaboration with other leading ...

Time January 29, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 27, 2026 — Hyperfine has announced results from the largest data set to date evaluating stroke detection with its ...

Time January 28, 2026
arrow
News | PET Imaging

Jan. 26, 2026 — Nuclidium, a clinical-stage radiopharmaceutical company developing a proprietary copper-based ...

Time January 27, 2026
arrow
News | Magnetic Resonance Imaging (MRI)

Jan. 20, 2026 — Hyperfine, the developer of the first FDA-cleared AI-powered portable MRI system for the brain — the ...

Time January 20, 2026
arrow
News | Mammography

Jan. 16, 2026 — Vega Imaging Informatics has announced the successful curation of the world’s largest digital breast ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — VizMark has received U.S. Food and Drug Administration FDA 510k clearance for VM1, a non-metal visual ...

Time January 19, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — Susan G. Komen, the world’s leading breast cancer organization commends Assemblymember Lori Wilson (D ...

Time January 16, 2026
arrow
News | Breast Imaging

Jan. 14, 2026 — iSono Health has announced the commercial launch of ATUSA, an FDA-cleared, wearable and automated 3D ...

Time January 14, 2026
arrow
Subscribe Now